JPWO2019222055A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222055A5 JPWO2019222055A5 JP2020563960A JP2020563960A JPWO2019222055A5 JP WO2019222055 A5 JPWO2019222055 A5 JP WO2019222055A5 JP 2020563960 A JP2020563960 A JP 2020563960A JP 2020563960 A JP2020563960 A JP 2020563960A JP WO2019222055 A5 JPWO2019222055 A5 JP WO2019222055A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- amino acid
- acid sequence
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008937 atopic dermatitis Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 229950003468 Dupilumab Drugs 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 108091003598 dupilumab Proteins 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 48
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 24
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000003112 inhibitor Substances 0.000 claims 20
- 230000002401 inhibitory effect Effects 0.000 claims 20
- 206010012438 Dermatitis atopic Diseases 0.000 claims 16
- 108090001123 antibodies Proteins 0.000 claims 8
- 102000004965 antibodies Human genes 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000038129 antigens Human genes 0.000 claims 8
- 108091007172 antigens Proteins 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 229940071643 Prefilled Syringe Drugs 0.000 claims 4
- 230000002730 additional Effects 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000003974 emollient agent Substances 0.000 claims 2
- 238000009121 systemic therapy Methods 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims 1
- 229960001334 Corticosteroids Drugs 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010057631 House dust allergy Diseases 0.000 claims 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 229940014456 MYCOPHENOLATE Drugs 0.000 claims 1
- 229960000951 Mycophenolic Acid Drugs 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 claims 1
- 206010046736 Urticarias Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000844 anti-bacterial Effects 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 230000000414 obstructive Effects 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 231100000486 side effect Toxicity 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000024A JP2024038234A (ja) | 2018-05-13 | 2024-01-04 | Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670824P | 2018-05-13 | 2018-05-13 | |
| US62/670,824 | 2018-05-13 | ||
| US201962840493P | 2019-04-30 | 2019-04-30 | |
| US62/840,493 | 2019-04-30 | ||
| PCT/US2019/031801 WO2019222055A1 (en) | 2018-05-13 | 2019-05-10 | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000024A Division JP2024038234A (ja) | 2018-05-13 | 2024-01-04 | Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523188A JP2021523188A (ja) | 2021-09-02 |
| JPWO2019222055A5 true JPWO2019222055A5 (es) | 2022-05-12 |
Family
ID=66641513
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563960A Pending JP2021523188A (ja) | 2018-05-13 | 2019-05-10 | Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
| JP2024000024A Pending JP2024038234A (ja) | 2018-05-13 | 2024-01-04 | Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000024A Pending JP2024038234A (ja) | 2018-05-13 | 2024-01-04 | Ｉｌ－４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11292847B2 (es) |
| EP (1) | EP3793597A1 (es) |
| JP (2) | JP2021523188A (es) |
| KR (1) | KR20210010518A (es) |
| CN (1) | CN112153982A (es) |
| AU (1) | AU2019270940A1 (es) |
| BR (1) | BR112020020387A2 (es) |
| CA (1) | CA3099066A1 (es) |
| MA (1) | MA52624A (es) |
| MX (1) | MX2020012064A (es) |
| SG (1) | SG11202009371WA (es) |
| WO (1) | WO2019222055A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| MX2016011132A (es) | 2014-02-28 | 2016-12-08 | Regeneron Pharma | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| WO2021026205A1 (en) * | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| JPH06510750A (ja) | 1991-05-03 | 1994-12-01 | セラジェン インク | 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子 |
| JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
| US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| ZA946875B (en) | 1993-09-07 | 1995-07-06 | Smithkline Beecham Corp | Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
| ES2259478T3 (es) | 1998-09-18 | 2006-10-01 | Dynavax Technologies Corporation | Metodos para tratar trastornos asociados con la ige y composiciones para este uso. |
| AU2001272925A1 (en) | 2000-05-26 | 2001-12-11 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| AU2001267917A1 (en) | 2000-07-26 | 2002-02-05 | Kenjirou Tsuchida | Antipruritic compositions and compositions promoting wound healing |
| US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
| CA2446108A1 (en) | 2001-05-11 | 2002-11-21 | Novartis Ag | Compositions for use in treating ige-associated disorders |
| DE60233519D1 (de) | 2001-05-23 | 2009-10-08 | Duotol Ab | Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten |
| WO2003048083A2 (en) | 2001-11-30 | 2003-06-12 | Biogen Idec Ma Inc. | Antibodies against monocyte chemotactic proteins |
| AU2003220525A1 (en) | 2002-03-29 | 2003-10-20 | Abgenix, Inc. | Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| SI2407485T1 (sl) | 2003-02-01 | 2016-09-30 | Tanox, Inc. | Visoko afinitetna anti-humana protitelesa IgE |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| CA2543982C (en) | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| CA2550933A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| CA2554596A1 (en) | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 specific polypetides and therapeutic uses thereof |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| PL2769992T3 (pl) | 2006-10-02 | 2021-08-02 | Regeneron Pharmaceuticals, Inc. | Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4 |
| NZ580553A (en) | 2007-03-22 | 2012-05-25 | Genentech Inc | Apoptotic anti- ige antibodies binding the membrane-bound ige |
| EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| WO2009061819A1 (en) | 2007-11-05 | 2009-05-14 | The Regents Of The University Of Colorado | Minimally-invasive measurement of esophageal inflammation |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| EP2376656A4 (en) | 2008-12-01 | 2012-05-16 | Cincinnati Children S Hospital Medical Ct | METHODS FOR DETERMINING THE EFFECTIVENESS OF GLUCOCORTICOID TREATMENT OF SOSHOPHILIC OOPHAGITIS |
| US20120088814A1 (en) | 2009-03-31 | 2012-04-12 | Isis Pharmaceuticals, Inc. | Methods of modulating an immune response to a viral infection |
| US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
| ES2534558T3 (es) | 2009-09-07 | 2015-04-24 | Dbv Technologies | Método de tratamiento de la esofagitis eosinofílica |
| US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
| EP2585075B8 (en) | 2010-06-24 | 2021-09-22 | ViroPharma Biologics LLC | Methods of treatment for esophageal inflammation |
| EA034617B1 (ru) | 2010-10-06 | 2020-02-27 | Ридженерон Фармасьютикалз, Инк. | Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r) |
| RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
| CA2824043A1 (en) | 2011-01-06 | 2012-07-12 | Marc E. Rothenberg | Esophageal cytokine expression profiles in eosinophilic esophagitis |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| US9928344B2 (en) | 2011-06-21 | 2018-03-27 | Children's Hospital Medical Center | Diagnostic methods of eosinophilic esophagitis |
| WO2013051928A1 (en) | 2011-10-06 | 2013-04-11 | N.V. Nutricia | Treatment of eosinophilic esophagitis |
| EA026456B1 (ru) | 2011-12-16 | 2017-04-28 | Атопикс Терапьютикс Лимитед | Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита |
| US20130243750A1 (en) | 2012-01-31 | 2013-09-19 | Genentech, Inc. | Anti-ige antibodies and methods using same |
| WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
| PT3470432T (pt) | 2012-08-21 | 2021-12-14 | Regeneron Pharma | Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r |
| NZ731864A (en) * | 2012-09-07 | 2022-07-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| WO2014059178A1 (en) | 2012-10-10 | 2014-04-17 | Rhode Island Hospital | Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis |
| US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| US10059771B2 (en) | 2013-06-21 | 2018-08-28 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| KR102368450B1 (ko) | 2014-02-21 | 2022-02-28 | 사노피 바이오테크놀로지 | Ｉｌ-4ｒ 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| MX2016011132A (es) | 2014-02-28 | 2016-12-08 | Regeneron Pharma | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. |
| EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| EP3416685A1 (en) | 2016-02-19 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
| US10485844B2 (en) * | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| CN111526920A (zh) | 2017-10-30 | 2020-08-11 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂来治疗或预防哮喘的方法 |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| WO2021026205A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
| MX2022014440A (es) | 2020-05-22 | 2023-02-27 | Regeneron Pharma | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. |
-
2019
- 2019-05-10 MX MX2020012064A patent/MX2020012064A/es unknown
- 2019-05-10 US US16/409,164 patent/US11292847B2/en active Active
- 2019-05-10 JP JP2020563960A patent/JP2021523188A/ja active Pending
- 2019-05-10 EP EP19726273.6A patent/EP3793597A1/en active Pending
- 2019-05-10 WO PCT/US2019/031801 patent/WO2019222055A1/en unknown
- 2019-05-10 MA MA052624A patent/MA52624A/fr unknown
- 2019-05-10 BR BR112020020387-4A patent/BR112020020387A2/pt unknown
- 2019-05-10 AU AU2019270940A patent/AU2019270940A1/en active Pending
- 2019-05-10 KR KR1020207035859A patent/KR20210010518A/ko unknown
- 2019-05-10 CN CN201980032103.7A patent/CN112153982A/zh active Pending
- 2019-05-10 CA CA3099066A patent/CA3099066A1/en active Pending
- 2019-05-10 SG SG11202009371WA patent/SG11202009371WA/en unknown
-
2022
- 2022-03-04 US US17/687,051 patent/US20220298250A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000024A patent/JP2024038234A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210130451A1 (en) | Treatment for rheumatoid arthritis | |
| Doroudchi et al. | Asthma biologics: comparing trial designs, patient cohorts and study results | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| US20010026801A1 (en) | Cytokine antagonists for the treatment of localized disorders | |
| IL294554B1 (en) | Methods for the treatment of chronic sinusitis with nasal polyps by adding an il-4r antagonist | |
| WO2016167263A1 (ja) | Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| US20230303677A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2019529560A5 (es) | ||
| JPWO2019222055A5 (es) | ||
| Dimov et al. | Immunomodulators for asthma | |
| Anselmo-Lima et al. | Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil | |
| Roy et al. | The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials | |
| JPWO2021026205A5 (es) | ||
| JP2024016237A5 (es) | ||
| JP2021147383A (ja) | アトピー性皮膚炎及び関連障害を処置するための方法 | |
| JPWO2021195530A5 (es) | ||
| KR20220104789A (ko) | 류마티스 관절염의 치료를 위한 btk 억제제 및 아바타셉트의 조합물 | |
| WO2022075476A1 (en) | Method for treating ox40 related disease | |
| RU2020140639A (ru) | Способы лечения атопического дерматита посредством введения ингибитора ил-4r | |
| Krishna et al. | P451 SUCCESSFUL TREATMENT OF MEPOLIZUMAB IN 14-YEAR OLD PATIENT WITH EGPA | |
| RU2024107446A (ru) | Способы лечения атопического дерматита посредством введения антагониста il-4r | |
| Jensena | Biomarkers in Chronic Obstructive Pulmonary Disease: Emerging Roles of Eosinophils and Procalcitonin | |
| Jancin | First-line inhaled steroids for pediatric asthma gain support | |
| Dutton | Asthma Prescription Numbers Slow Down: Monoclonal Antibodies Lead the Pipeline in the Development of Novel Therapeutics | |
| DM et al. | From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil driven diseases |